University of Maryland School of Medicine logo
UMSOM Assistant

2026 News

  • Home
  • News
  • Press Releases
  • 2026 News

Commonly Cited Flu Vaccine Effectiveness Estimates May Give Incomplete Picture, UMSOM Study Finds

NewsPress Releases2026 NewsCommonly Cited Flu Vaccine Effectiveness Estimates May Give Incomplete Picture, UMSOM Study Finds

November 16, 2026

Public health agencies and the news media frequently tell Americans that influenza vaccines are 40 to 60 percent effective when they are well matched to circulating viruses. But how often does that description reflect what happens during a typical influenza season?

Justin R. Ortiz, MD, MSResearchers at the University of Maryland School of Medicine examined this question using vaccine effectiveness estimates from 18 influenza seasons. Their findings, published in JAMA Network Open, suggest that the commonly cited range does not adequately convey the variability in protection from year to year.

The researchers found that influenza vaccines had a median effectiveness of 39.5 percent against medically attended influenza. Effectiveness varied substantially across seasons, and their analysis estimated a 95 percent prediction interval of approximately 16 to 59 percent for vaccine effectiveness in a single future season.

Importantly, antigenic mismatch—where the vaccine formulation doesn’t match the strains that are circulating--was reported in 11 of 18 seasons studied. The 40 to 60 percent effectiveness message is often qualified by the assumption that vaccine strains are well matched to circulating viruses, but that condition was not consistently met.

"Our question was whether the numbers we routinely use to describe flu vaccine effectiveness give people a realistic understanding of the protection they can expect," said senior author Justin Ortiz, MD, MS, Professor of Medicine at UMSOM and a researcher at its Center for Vaccine Development and Global Health (CVD). "The 40 to 60 percent range may describe some seasons, but it doesn't adequately reflect the variability we see over time. We need to communicate that uncertainty without losing sight of the substantial benefits of vaccination."

The findings do not change recommendations for annual influenza vaccination, which remains the best available means of preventing influenza and reducing its complications. Rather, they highlight an opportunity to improve how vaccine effectiveness is explained to the public and reinforce the need to develop vaccines that provide more consistent protection across seasons.

Matthew Wolpert, MD“Communicating this variability more clearly can help patients, health care providers, and public health officials develop more realistic expectations about influenza vaccination,” said the study’s first author, Matthew Wolpert, MD, who is a second-year internal medicine resident at the University of Maryland Medical Center.  “For patients and health care providers, the message is clear that annual flu shots remain our best option for now as we continue to develop vaccines that provide more predictable and lasting protection.”

Why Annual Vaccination Still Matters

Seasonal influenza causes substantial illness, hospitalization, and death each year in the United States, particularly among older adults, young children, pregnant women, and people with underlying medical conditions.

Even when influenza vaccines do not prevent every infection, vaccination remains an important means of reducing the burden of influenza and its complications. During the 2023-2024 season, flu vaccination prevented 9.8 million flu-related illnesses, 120,000 hospitalizations, and 7,900 deaths, according to the CDC.

The study measured vaccine effectiveness against medically attended influenza, not against hospitalization or death. Even in seasons when effectiveness against influenza illness is relatively low, vaccination can provide important protection against serious complications.

Building Better Influenza Vaccines

The study also highlights a longstanding challenge in influenza prevention: the need to develop vaccines that provide broader and more durable protection against an ever-changing virus.

Current seasonal influenza vaccines must be updated regularly to account for anticipated changes in circulating influenza strains. When the selected vaccine strains do not closely match circulating viruses, protection may be reduced.

At UMSOM's CVD, Dr. Ortiz and his colleagues are pursuing new approaches to influenza prevention, including vaccines designed to provide broader protection against multiple influenza strains.

The goal is to move beyond vaccines whose effectiveness depends heavily on predicting which viruses will circulate during an upcoming season.

The research was supported by a University of Maryland, Baltimore Targeted Pivoting Programmatic Research Grant awarded to Dr. Ortiz's research team. UMSOM faculty members Yuanyuan Liang, PhD, Professor of Epidemiology & Public Health, and Meagan Fitzpatrick, PhD, Associate Professor of Medicine, were co-authors on this study.

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

Monday, February 02, 2026

University of Maryland School of Medicine Launches Clinical Trial of Investigative Nasal Spray Medicine to Prevent Illnesses from Respiratory Viruses

Last year, at least one million people in the U.S. were hospitalized for respiratory virus illnesses like the flu or COVID-19, according to the Centers for Disease Control and Prevention. Many of these individuals were at higher risk of getting infections due to living or working around young children who contract more respiratory infections. A new clinical trial led by researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD) will test a new experimental intranasal spray designed to boost immune defenses and reduce illness from respiratory viruses.

Wednesday, September 12, 2018

UMSOM Influenza Expert Talks about Risk of Pandemics in Globally Connected World

Wilbur Chen, MD, Associate Professor of Medicine and a vaccine development specialist at the University of Maryland School of Medicine, discussed on WYPR’s “On the Record” how influenza and other diseases can now more easily spread around the world. In an interview with Radio Show Host Sheila Kast, Dr. Chen discussed how the Spanish influenza pandemic in 1918, which led to deaths between 50 and 100 million, actually spread at a slower pace than diseases today.

Thursday, October 05, 2017

UM SOM Researchers Identify Protein That Could Reduce Death and Improve Symptoms in Influenza and Other Infectious Diseases

A new study by researchers at the University of Maryland School of Medicine has identified an innovative strategy for treating influenza, and perhaps other infectious diseases as well. Scientists showed that a small protein called retrocyclin-101 (RC-101) could potentially improve the symptoms and mortality associated with the flu and possibly other types of infectious illness as well.

University of Maryland School of Medicine logo
  • Departments
  • Programs
  • Research Centers
  • Institutes
  • Graduate Education
  • CIBR Cores
  • Offices of the Dean
    • University of Maryland, Baltimore
    • University of Maryland Medical Center
    • Medical Alumni Association of the University of Maryland
    • Health Sciences and Human Services Library
University of Maryland School of Medicine
655 W. Baltimore Street
Baltimore, MD 21201
Contact Us

© University of Maryland School of Medicine

    • Webmaster
    • Web Accessibility
    • Site Index
    • UMB Hotline
    • Employment
    • Map